Patents by Inventor Gunter Holzemann
Gunter Holzemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8058277Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in Claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolyties and/or antihypertonics. They can furthermore be employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses.Type: GrantFiled: October 3, 2008Date of Patent: November 15, 2011Assignee: Merck Patent GmbHInventors: Oliver Schadt, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7968551Abstract: Chromenoneindole derivatives of the formula (I), in which R1, R2, R3, R, A and B are as defined in Claim 1, and pharmaceutically usable prodrugs, derivatives, solvates, stereoisomers and salts thereof, exhibit particular actions on the central nervous system, in particular 5-HT reuptake-inhibiting and 5-HTx-agonistic and/or -antagonistic actions. They are distinguished by particularly high bioavailability and particularly high inhibition of 5-HT reuptake.Type: GrantFiled: March 8, 2004Date of Patent: June 28, 2011Assignee: Merck Patent GmbHInventors: Kai Schiemann, Henning Böttcher, Timo Heinrich, Günter Hölzemann, Christoph Van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Patent number: 7829565Abstract: Compounds of the formula (I), the use thereof for the preparation of a medicament for the treatment of diseases associated with the serotonin receptor and/or serotonin reuptake, in particular for the preparation of a medicament as anxiolytic, antidepressant, neuroleptic and/or antihypertonic and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, such as bulimia, and/or sexual dysfunctions. The compounds bind to the 5-HT1A receptor.Type: GrantFiled: May 24, 2004Date of Patent: November 9, 2010Assignee: Merck Patent GmbHInventors: Timo Heinrich, Henning Böttcher, Kai Schiemann, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Publication number: 20090291963Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolytics and/or antihypertonics.Type: ApplicationFiled: July 29, 2009Publication date: November 26, 2009Inventors: Oliver SCHADT, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Publication number: 20090247584Abstract: Compounds of the formula (I), in which R1, R2?, R2?, R2??, R3 and n are as defined in Claim 1, are effectors of the nicotinic and/or muscarinic acetylcholine receptor and are suitable for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.Type: ApplicationFiled: February 26, 2009Publication date: October 1, 2009Inventors: Gunter HOLZEMANN, Helmut Prucher, Kai Schiemann, Joachim Leibrock, Hartmut Greiner, Christa Burger, Laurie von Melchner
-
Patent number: 7572796Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolytics and/or antihypertonics. They can furthermore be employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses.Type: GrantFiled: April 11, 2003Date of Patent: August 11, 2009Assignee: Merck Patent GmbHInventors: Oliver Schadt, Henning Böttcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Publication number: 20090054459Abstract: Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R1, D, E, R12, p, X1, E, G, X2 and Z are as defined in claim 1, exhibit particular actions on the central nervous system, especially 5HT reuptake-inhibiting and 5 HTx-agonistic and/or -antagonistic actions and in particular serotonin-agonistic and -antagonistic properties and can be employed as antipsychotics, neuroleptics, antidepressants, anxiolyties and/or antihypertonics.Type: ApplicationFiled: October 3, 2008Publication date: February 26, 2009Inventors: Oliver Schadt, Henning Bottcher, Joachim Leibrock, Kai Schiemann, Timo Heinrich, Gunter Holzemann, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7482465Abstract: The invention relates to indol derivatives of Formula (I) in which R1, R2, R3, X, A, n, m and p have the meanings indicated above.Type: GrantFiled: November 17, 2003Date of Patent: January 27, 2009Assignee: Merck Patent GmbHInventors: Günter Hölzemann, Helene Crassier, Henning Böttcher, Timo Heinrich, Kai Schiemann, Joachim Leibrock, Chrisoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7432282Abstract: Novel indole derivatives of the formula (I), in which X, Y, R1, R1?, m and n have the meanings indicated in Patent Claim 1, have a strong affinity to the 5-HT1A and in some cases to the 5-HT1D receptors.Type: GrantFiled: October 30, 2003Date of Patent: October 7, 2008Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Günter Hölzemann, Kai Schiemann, Timo Heinrich, Henning Böttcher, Joachim Leibrock, Christoph van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7425574Abstract: Novel benzofuranoxyethylamines of the formula (I), in which R1, R2, R3, R4, m and n have the meanings indicated in Patent Claim (1), which have a strong affinity to the 5 HT1A receptors and/or 5HT1D receptors. The compounds inhibit serotonin reuptake, exhibit serotonin-agonistic and -antagonistic properties and are suitable as antidepressants, anxiolytics, antipsychotics, neuroleptics and/or antihypertonics.Type: GrantFiled: January 19, 2004Date of Patent: September 16, 2008Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Günter Hölzemann, Kai Schiemann, Henning Böttcher, Timo Heinrich, Christoph Seyfried, Joachim Leibrock, Chrisoph Van Amsterdam, Gerd Bartoszyk
-
Patent number: 7262216Abstract: Novel benzofuran derivatives of the formula (I) in which R1, R2, X, Y, Z and m have the meanings indicated in Patent Claim 1, they have a strong affinity to the 5-HT1A receptors.Type: GrantFiled: January 10, 2004Date of Patent: August 28, 2007Assignee: Merck Patent GesellschaftInventors: Günter Hölzemann, Henning Böttcher, Kai Schiemann, Timo Heinrich, Joachim Leibrock, Christoph Van Amsterdam, Gerd Bartoszyk, Christoph Seyfried
-
Patent number: 7253202Abstract: Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R1, R2, R3, R4, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition.Type: GrantFiled: November 27, 2003Date of Patent: August 7, 2007Assignee: Merck Patent GmbHInventors: Timo Heinrich, Henning Böttcher, Kai Schiemann, Günter Hölzemann, Christoph van Amsterdam, Gerd Bartoszyk, Hartmut Greiner, Christoph Seyfried, Michel Brunet, Jean Zeiller, Jean Berthelon
-
Publication number: 20070099933Abstract: Compounds of the formula (I), the use thereof for the preparation of a medicament for the treatment of diseases associated with the serotonin receptor and/or serotonin reuptake, in particular for the preparation of a medicament as anxiolytic, antidepressant, neuroleptic and/or antihypertonic and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, such as bulimia, and/or sexual dysfunctions.Type: ApplicationFiled: May 24, 2004Publication date: May 3, 2007Inventors: Timo Heinrich, Henning Bottcher, Kai Schiemann, Gunter Holzemann, Christoph van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Publication number: 20060258680Abstract: Chromenoneindole derivatives of the formula (I), in which R1, R2, R3, R, A and B are as defined in Claim 1, and pharmaceutically usable prodrugs, derivatives, solvates, stereoisomers and salts thereof, exhibit particular actions on the central nervous system, in particular 5-HT reuptake-inhibiting and 5-HTx-agonistic and/or -antagonistic actions. They are distinguished by particularly high bioavailability and particularly high inhibition of 5-HT reuptake.Type: ApplicationFiled: March 8, 2004Publication date: November 16, 2006Inventors: Kai Schiemann, Henning Böttcher, Timo Heinrich, Günter Hölzemann, Christoph Van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Publication number: 20060160824Abstract: Compounds of the formula (I), the use thereof for the preparation of a medicament for the treatment of diseases associated with the serotonin receptor and/or serotonin reuptake, in particular for the preparation of a medicament as anxiolytic, antidepressant, neuroleptic and/or antihypertonic and/or for positively influencing obsessive-compulsive disorder (OCD), sleeping disorders, tardive dyskinesia, learning disorders, age-dependent memory disorders, eating disorders, such as bulimia or IBS, and/or sexual dysfunctions.Type: ApplicationFiled: May 24, 2004Publication date: July 20, 2006Inventors: Timo Heinrich, Henning Bottcher, Kai Schiemann, Gunter Holzemann, Christoph van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Publication number: 20060142372Abstract: Novel benzofuran derivatives of the formula (I) in which R1, R2, X, Y, Z and m have the meanings indicated in Patent Claim 1, they have a strong affinity to the 5-HT1A receptors. The compounds inhibit serotonin reuptake, exhibit serotonin-agonistic and -antagonistic properties and are suitable as antidepressants, anxiolytics, antipsychotics, neuroleptics and/or antihypertonics.Type: ApplicationFiled: January 10, 2004Publication date: June 29, 2006Inventors: Gunter Holzemann, Henning Bottcher, Kai Schiemann, Timo Heinrich, Joachim Leibrock, Christoph Van Amsterdam, Gerd Bartpszyk, Christoph Seyfried
-
Publication number: 20060122191Abstract: N-(indolethyl-)cycloamine compounds of the formula (I): in which R1?, R1? X, Ar, and n have a meaning indicated in Claim 1, are serotonin reuptake inhibitors (SSRIs) and effectors of the serotonergic receptors 5-HT1A and 5-HT2A. They are therefore suitable for the prophylaxis or treatment of various diseases of the central nervous system, such as depression, dyskinesia, Parkinson's disease, dementia, strokes, schizophrenia, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairment, pain, sleeping disorders and neurodegenerative diseases.Type: ApplicationFiled: November 27, 2003Publication date: June 8, 2006Inventors: Timo Heinrich, Henning Bottcher, Kali Schiemann, Gunter Holzemann, Christoph Van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
-
Publication number: 20050131021Abstract: Compounds of the formula (1), in which R1, R2?, R2?, R2??, R3 and n are as defined in claim 1, are effectors of the nicotinic and/or muscarinic acetylcholine receprot and are suitable for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.Type: ApplicationFiled: December 17, 2002Publication date: June 16, 2005Applicant: Merck Patent GmbHInventors: Gunter Holzemann, Helmut Prucher, Kai Schiemann, Joachim Leibrock, Hartmut Greiner, Christa Burger, laurie von Melchner
-
Publication number: 20040043937Abstract: The invention relates to compounds of formula (I) B-Q-X1, wherein B is a bioactive, cell adhesive mediating molecule, selected from the group (i) and Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (ii), Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (iii), Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (iv), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg (v), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn (vi), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg (vii), wherein (i) X, Y, Z, R2, R3, R4, A, Ar, Hal, Het, Het1, n, m, o, p, q, s, t have the meanings cited in claim 1, Q is absent or is an organic spacer molecule, X1 is an anchor molecule selected from the group cited in claim 1, and the salts thereof, which can be used as integrin inhibitors particularly for treatment of illness, deficiencies and inflammations caused by implants and osteolytic illnesses such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, in addition to the acceleration and strengthening of the integration process of implants or the biocompatibType: ApplicationFiled: February 14, 2003Publication date: March 4, 2004Inventors: Jorg Meyer, Berthold Nies, Michel Dard, Gunter Holzemann, Horst Kessler, Martin Kantlehner, Ulrich Hersel, Christoph Gibson, Gabor Sulyok
-
Publication number: 20040029782Abstract: The invention relates to compounds of formula (1) I-Q-X1, wherein B is bioactive cell adhesive mediating molecule. Q is absent or is an inorganic spacer molecule and X1 is an anchor molecule, selected from the group Lys.(CO—CH —(CH2)n—PO3H2)2(I)-Lys[-Lys-(CO—CH2—(CH2)a—PO3H2)2]2(ii) or -Lys-(Lys[-Lys-(CO—CH2—(CH2)n—PO3H2]2 (iii), and n independently represents 0, 1, 2 or 3, wherein a free amino group of group B is linked in peptide form to a free carboxyl group of the spacer molecule Q or of the anchor molecule X1 or a free amino group of the radical Q is linked in peptide form to a free carboxyl group of the radical X1. The invention also relates to the salts thereof.Type: ApplicationFiled: February 14, 2003Publication date: February 12, 2004Inventors: J?ouml;rg Meyer, Berthold Nies, Michel Dard, Gunter Holzemann, Horst Kessler, Martin Kantlehner, Ulrich Hersel, Christoph Gibson, Gabor Sulyok